NewsResearch
A Personalized mRNA Cancer Vaccine Just Passed a Phase 3 Test in Melanoma
Merck and Moderna say intismeran autogene plus pembrolizumab kept melanoma from coming back longer than pembrolizumab alone. What the trial measured, what it has not yet shown, and why the result is being called a first.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
What was announced
On 19 August 2026, Merck and Moderna said their phase 3 trial INTerpath-001 had met its main goal. People whose melanoma had been fully removed by surgery went longer without it coming back when a personalized mRNA therapy was added to pembrolizumab, compared with pembrolizumab alone.
The therapy is called intismeran autogene. Pembrolizumab is sold as Keytruda and is already standard care in this setting.
Two things are worth saying at the top. The trial is real and large. And the actual numbers have not been published yet.
Who was in the trial
INTerpath-001 enrolled 1,137 people with cutaneous melanoma at stage IIB, IIC, III or IV that had been completely removed by surgery. None had received systemic treatment for it before.
They were assigned at random, two to one, to one of two groups. One group got intismeran autogene plus pembrolizumab. The other got pembrolizumab alone.
That comparison matters. The trial did not test the new therapy against nothing. It tested whether adding it to an existing treatment does more than that treatment on its own.
What the treatment involves
Intismeran autogene is not one product made in a batch. Each dose is built for one person, from the genetic features of their own tumor. Our companion piece explains how an individualized neoantigen therapy is made.
In the trial, people received up to nine doses of intismeran, three weeks apart, alongside pembrolizumab every six weeks for up to nine cycles. That is roughly a year of treatment in total.
What the trial measured
The main measure was recurrence-free survival: how long people lived without the melanoma returning. The trial met it.
A second measure, distant metastasis-free survival, asks something narrower and arguably more important — how long people went without the cancer appearing somewhere far from where it started. The trial met that too.
Overall survival, meaning how long people lived, is still being followed and is not yet mature. That is not a criticism of the trial. It is simply where the data stands, and it is the single most useful thing to keep in mind when reading coverage of this result. We explain why in what recurrence-free survival actually measures.
What has not been released
The companies announced what statisticians call topline results, from a planned interim look at the data. They have not published the hazard ratios, the confidence intervals, or the survival curves.
Without those, nobody outside the trial can say how large the benefit is. "Met its endpoint" means the difference was unlikely to be chance. It does not say whether the difference was small or dramatic.
An earlier, smaller phase 2b trial of the same combination, KEYNOTE-942, reported a 49% lower risk of recurrence or death (hazard ratio 0.51, 95% confidence interval 0.294 to 0.887). Phase 2 results often shrink when a larger trial repeats them, so that figure is context, not a prediction.
Safety
The companies said the safety profile matched what earlier studies of the combination had shown, with no new safety signals. Detailed side-effect rates for this trial have not been released.
Pembrolizumab alone can cause immune-related side effects affecting the thyroid, bowel, liver, lungs and skin. Adding a second immune-directed treatment is a reasonable thing to want the full numbers on.
What people involved said
Professor Georgina Long, the trial's principal investigator, said this is the first phase 3 study to show that intismeran given with pembrolizumab can reduce the risk of recurrence or death.
Moderna's chief executive, Stéphane Bancel, called the findings a pivotal moment for cancer research. Merck's Dean Y. Li said they reinforce the promise of a more personalized approach.
Company statements about their own unpublished trial are a starting point, not an independent assessment.
What happens next
The full data will be presented at an international medical meeting, and the companies say they will talk to regulators about filing for approval.
Intismeran autogene is not approved anywhere. Outside a clinical trial, it is not something you can ask for.
If you are weighing up options after melanoma surgery, melanoma treatment by stage covers what is available now, and finding a clinical trial explains how to look for studies you might join.
Sources
- https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/
- https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines
- https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Melanoma. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.